{"nctId":"NCT01838590","briefTitle":"Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection","startDateStruct":{"date":"2013-03"},"conditions":["Hepatitis C Virus"],"count":103,"armGroups":[{"label":"SOF+RBV 12 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV 24 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]}],"interventions":[{"name":"SOF","otherNames":["Sovaldi®","GS-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Treatment experienced and naïve subjects\n* Chronic genotype 4 HCV-infection\n* Not co-infected with HIV\n* Screening laboratory values within defined thresholds\n* Use of highly effective contraception methods\n* Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.\n\nExclusion Criteria:\n\n* History of any other clinically significant chronic liver disease\n* Pregnant or nursing female or male with pregnant female partner\n* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol\n* Excessive alcohol ingestion or significant drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"70.4","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"88.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"74.1","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"70.4","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"88.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as\n\n* Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Virologic Relapse","description":"Virologic relapse was defined as confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"29.6","spread":null},{"groupId":"OG002","value":"4.2","spread":null},{"groupId":"OG003","value":"11.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Fatigue","Headache","Insomnia","Anaemia","Dyspepsia"]}}}